Following the recommendations of the authorities for the coronavirus pandemic, SARA Pharm has taken the necessary measures to ensure the continuity of its activity. The current projects are on-going. The laboratory is operational and the necessary precautions have been taken to allow the safe reception of samples. We do not foresee any impact on our activity to date. In the event of an evolution, we will not fail to keep you informed.


We are proud that the Nifuroxazide polymorph screening case-study performed in-house by SARA Pharm was recently published in CrystEngComm:!divAbstract.

SARA Pharm Solutions will attend Biotech Outsourcing Strategies cmc on 27th & 28th June 2017, in Basel, Switzerland.

Please contact us in order to arrange a meeting.